These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 16144980

  • 1. Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406.
    Sulpizio AC, Pullen MA, Edwards RM, Louttit JB, West R, Brooks DP.
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1306-13. PubMed ID: 16144980
    [Abstract] [Full Text] [Related]

  • 2. Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat.
    Kubota E, Dean RG, Hubner RA, Casley DJ, Johnston CI, Burrell LM.
    Clin Sci (Lond); 2003 Sep; 105(3):339-45. PubMed ID: 12741953
    [Abstract] [Full Text] [Related]

  • 3. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.
    Sulpizio AC, Pullen MA, Edwards RM, Brooks DP.
    J Pharmacol Exp Ther; 2004 Jun; 309(3):1141-7. PubMed ID: 14769834
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
    Raasch W, Dominiak P, Dendorfer A.
    J Hypertens; 2005 Aug; 23(8):1597-604. PubMed ID: 16003188
    [Abstract] [Full Text] [Related]

  • 5. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
    Hegde LG, Yu C, Renner T, Thibodeaux H, Armstrong SR, Park T, Cheruvu M, Olsufka R, Sandvik ER, Lane CE, Budman J, Hill CM, Klein U, Hegde SS.
    J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats.
    Pu Q, Touyz RM, Schiffrin EL.
    J Hypertens; 2002 May; 20(5):899-907. PubMed ID: 12011651
    [Abstract] [Full Text] [Related]

  • 12. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
    Blais C, Fortin D, Rouleau JL, Molinaro G, Adam A.
    J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
    [Abstract] [Full Text] [Related]

  • 13. Direct inhibition of neutral endopeptidase in vasopeptidase inhibitor-mediated amelioration of cardiac remodeling in rats with chronic heart failure.
    Maki T, Nasa Y, Tanonaka K, Takahashi M, Takeo S.
    Mol Cell Biochem; 2003 Dec; 254(1-2):265-73. PubMed ID: 14674706
    [Abstract] [Full Text] [Related]

  • 14. Chronic vasopeptidase inhibition restores endothelin-converting enzyme activity and normalizes endothelin levels in salt-induced hypertension.
    Quaschning T, d'Uscio LV, Shaw S, Viswambharan H, Ruschitzka FT, Lüscher TF.
    Nephrol Dial Transplant; 2001 Jun; 16(6):1176-82. PubMed ID: 11390717
    [Abstract] [Full Text] [Related]

  • 15. Omapatrilat increases renal endothelin in deoxycorticosterone acetate-salt hypertensive rats.
    Elmarakby AA, Morsing P, Pollock JS, Pollock DM.
    Vascul Pharmacol; 2003 Dec; 40(5):253-9. PubMed ID: 15259792
    [Abstract] [Full Text] [Related]

  • 16. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice.
    Jandeleit-Dahm K, Lassila M, Davis BJ, Candido R, Johnston CI, Allen TJ, Burrell LM, Cooper ME.
    J Hypertens; 2005 Nov; 23(11):2071-82. PubMed ID: 16208151
    [Abstract] [Full Text] [Related]

  • 17. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat.
    Dalzell JR, Seed A, Berry C, Whelan CJ, Petrie MC, Padmanabhan N, Clarke A, Biggerstaff F, Hillier C, McMurray JJ.
    Cardiovasc Ther; 2014 Feb; 32(1):13-8. PubMed ID: 24138103
    [Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor.
    Azizi M, Massien C, Michaud A, Corvol P.
    Hypertension; 2000 Jun; 35(6):1226-31. PubMed ID: 10856268
    [Abstract] [Full Text] [Related]

  • 19. Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake.
    Azizi M, Lamarre-Cliche M, Labatide-Alanore A, Bissery A, Guyene TT, Ménard J.
    J Am Soc Nephrol; 2002 Oct; 13(10):2454-63. PubMed ID: 12239234
    [Abstract] [Full Text] [Related]

  • 20. In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat.
    Hubner RA, Kubota E, Casley DJ, Johnston CI, Burrell LM.
    J Hypertens; 2001 May; 19(5):941-6. PubMed ID: 11393678
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.